Mettler Toledo (NYSE:MTD) announced its earnings results on Thursday. The medical instruments supplier reported $3.74 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $3.73 by $0.01, Bloomberg Earnings reports. Mettler Toledo had a return on equity of 93.09% and a net margin of 13.50%. The company had revenue of $660.82 million for the quarter, compared to analyst estimates of $651.87 million. During the same period in the prior year, the company posted $3.34 EPS. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. Mettler Toledo updated its Q2 guidance to $4.55 to $4.60 EPS.
Shares of MTD stock opened at $552.97 on Friday. The company has a current ratio of 1.46, a quick ratio of 1.09 and a debt-to-equity ratio of 1.75. The stock has a market capitalization of $14,641.79, a PE ratio of 31.47, a PEG ratio of 2.20 and a beta of 1.21. Mettler Toledo has a fifty-two week low of $540.78 and a fifty-two week high of $697.26.
Hot Medical Stocks To Invest In 2019: GTT Communications, Inc.(GTT)
- [By Logan Wallace]
These are some of the media stories that may have impacted Accern Sentiment Analysis’s scoring:
Get GTT Communications alerts:
GTT to Present at Spring 2018 Investor Conferences (finance.yahoo.com) Unified Communications Week in Review: Firstcom, 8×8, RingCentral (unified-communications.tmcnet.com) RingCentral, SD-WAN vendors team up to deliver UCaaS (searchunifiedcommunications.techtarget.com) GTT Communications (GTT) CEO Richard Calder Sells 6,000 Shares (americanbankingnews.com) GTT Communications (GTT) EVP Chris Mckee Sells 7,000 Shares (americanbankingnews.com)
GTT has been the topic of several recent research reports. Oppenheimer increased their price objective on GTT Communications from $52.00 to $68.00 in a research report on Tuesday, February 27th. William Blair reiterated a “buy” rating on shares of GTT Communications in a research report on Wednesday, March 28th. Craig Hallum reiterated a “buy” rating and set a $60.00 price objective (up from $50.00) on shares of GTT Communications in a research report on Monday, February 26th. SunTrust Banks increased their price objective on GTT Communications to $60.00 and gave the company a “buy” rating in a research report on Friday, March 2nd. Finally, Jefferies Group increased their price objective on GTT Communications to $62.00 and gave the company a “buy” rating in a research report on Friday, March 2nd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus price target of $57.22.
- [By ]
In the Lightning Round, Cramer was bullish on GTT Communications (GTT) , Steel Dynamics (STLD) , Nucor (NUE) , Marriott International (MAR) , MGM Resorts (MGM) and Twitter (TWTR) .
- [By Lisa Levin]
Analysts at KeyBanc upgraded GTT Communications, Inc. (NYSE: GTT) from Sector Weight to Overweight.
GTT Communications shares fell 0.64 percent to $46.35 in pre-market trading.
- [By ]
GTT Communications (GTT) : “I think they have a great business model. I say buy, buy, buy.”
Steel Dynamics (STLD) : “That’s a great steel company and the only one I’ll recommend other than Nucor (NUE) .”
Hot Medical Stocks To Invest In 2019: AMERISAFE, Inc.(AMSF)
- [By Ethan Ryder]
BidaskClub lowered shares of AMERISAFE (NASDAQ:AMSF) from a hold rating to a sell rating in a report released on Friday.
Other research analysts have also issued reports about the stock. TheStreet raised shares of AMERISAFE from a c+ rating to a b rating in a report on Thursday, April 26th. ValuEngine raised shares of AMERISAFE from a hold rating to a buy rating in a report on Thursday, March 1st. Boenning Scattergood reaffirmed a hold rating on shares of AMERISAFE in a report on Tuesday, February 27th. Keefe, Bruyette & Woods initiated coverage on shares of AMERISAFE in a report on Thursday, April 5th. They issued a market perform rating and a $54.00 price target for the company. Finally, Zacks Investment Research lowered shares of AMERISAFE from a hold rating to a strong sell rating in a report on Tuesday, March 6th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company’s stock. AMERISAFE currently has a consensus rating of Hold and a consensus target price of $63.00.
- [By Shane Hupp]
Amerisafe, Inc. (NASDAQ:AMSF) EVP Vincent J. Gagliano sold 249 shares of Amerisafe stock in a transaction that occurred on Tuesday, May 22nd. The shares were sold at an average price of $60.15, for a total value of $14,977.35. Following the transaction, the executive vice president now owns 17,178 shares of the company’s stock, valued at $1,033,256.70. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
- [By Max Byerly]
ILLEGAL ACTIVITY NOTICE: “$0.73 Earnings Per Share Expected for Amerisafe, Inc. (AMSF) This Quarter” was first posted by Ticker Report and is the property of of Ticker Report. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at www.tickerreport.com/banking-finance/3362844/0-73-earnings-per-share-expected-for-amerisafe-inc-amsf-this-quarter.html.
Hot Medical Stocks To Invest In 2019: Houston Wire & Cable Company(HWCC)
- [By Max Byerly]
Houston Wire & Cable (NASDAQ:HWCC) hit a new 52-week high and low during mid-day trading on Wednesday after an insider bought additional shares in the company. The stock traded as low as $8.40 and last traded at $8.35, with a volume of 604 shares traded. The stock had previously closed at $7.90.
Hot Medical Stocks To Invest In 2019: Ionis Pharmaceuticals, Inc.(IONS)
- [By Brian Orelli]
Pfizer (NYSE:PFE) threw Alnylam and fellow ATTR drugmaker Ionis Pharmaceuticals (NASDAQ:IONS) a curveball in March, releasing positive results from a trial testing its ATTR drug tafamidis in patients with ATTR cardiomyopathy. But Alnylam isn’t backing down with potential plans to run a trial comparing its next-generation TTR drug, ALN-TTRsc02, against tafamidis, as outlined by Akshay Vaishnaw, Alnylam’s executive vice president of research and development:
- [By Lisa Levin] Gainers
AGM Group Holdings Inc. (NASDAQ: AGMH) shares climbed 30.3 percent to $11.05 after climbing 34.60 percent on Thursday.
Limelight Networks, Inc. (NASDAQ: LLNW) jumped 21.2 percent to $4.9699 following a first-quarter earnings beat. The company also raised its fiscal 2018 estimates.
Telefonaktiebolaget LM Ericsson (NASDAQ: ERIC) shares climbed 18.8 percent to $7.89 after reporting strong Q1 earnings.
Farmers Capital Bank Corp (NASDAQ: FFKT) gained 15.4 percent to $48.75. WesBanco Inc (NASDAQ: WSBC) announced an agreement and plan of merger with Farmers Capital Bank Corporation.
TransUnion (NYSE: TRU) climbed 10.2 percent to $66.76 after the company posted upbeat Q1 results and issued a strong forecast for the second quarter. TransUnion announced plans to acquire Callcredit.
Myomo, Inc. (NYSE: MYO) shares gained 9.2 percent to $3.9299 after rising 8.11 percent on Thursday.
Pinnacle Foods Inc (NYSE: PF) gained 8.8 percent to $60.04 after a 13-D filing from Jana Partners showed an increased stake in the comapny, from 1.42 million shares at the end of last quarter to 10.83 million shares, or a 9.3-percent stake.
Associated Banc-Corp (NYSE: ASB) shares climbed 8.8 percent to $26.70 following upbeat Q1 earnings.
OFG Bancorp (NYSE: OFG) gained 8.5 percent to $12.80 after reporting Q1 results.
Cleveland-Cliffs Inc. (NYSE: CLF) climbed 7.5 percent to $7.73 following Q1 results.
Seaspan Corporation (NYSE: SSW) shares climbed 6.7 percent to $7.50. Deutsche Bank upgraded Seaspan from Hold to Buy.
General Electric Company (NYSE: GE) shares rose 4.6 percent to $14.63 after the company reported better-than-expected earnings for its first quarter.
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) rose 4.3 percent to $47.80. Biogen and Ionis have expanded their strategic collaboration to develop drug candidates for a broad range of neurological diseases.
Check out these big penny stock gainers and losers
- [By Brian Feroldi, Keith Speights, and Sean Williams]
With that in mind, we asked a team of Motley Fool investors to highlight a biotech stock that they think is a strong buy right now. Here’s why they picked Exelixis (NASDAQ:EXEL), Celgene (NASDAQ:CELG), and Ionis Pharmaceuticals (NASDAQ:IONS).
- [By Cory Renauer]
Although Spinraza’s trajectory could quickly reverse, Biogen made a smart move by expanding its investment into the company that discovered it,Ionis Pharmaceuticals(NASDAQ:IONS). Unfortunately, Ionis probably won’t be adding any candidates to Biogen’s ultra-riskylate-stage pipeline right away.
- [By Chris Lange]
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) shares made a handy gain on Friday after the firm announced an expanded strategic collaboration with Biogen Inc. (NASDAQ: BIIB). Through this partnership, these companies are planning to tackle and develop novel antisense drug candidates for a broad range of neurological diseases.
Hot Medical Stocks To Invest In 2019: Smith & Nephew SNATS, Inc.(SNN)
- [By Lisa Levin]
Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
Arcadia Biosciences, Inc. (N
- [By Benzinga News Desk]
Weight Watchers (NYSE: WTW) is tipping the scales on Wall Street: Link
USA Nonfarm Payrolls for Apr 164.0K vs 189.0K Est; Prior 103.0K. Private Payrolls for Apr 168.0K vs 194.0K Est; Prior 102.0K
Unemployment Rate for Apr 3.90% vs 4.00% Est; Prior 4.10%
New York Fed President William Dudley is set to speak at 12:45 p.m. ET.
The Baker Hughes North American rig count report for the latest week is schedule for release at 1:00 p.m. ET.
Federal Reserve Bank of San Francisco President John Williams will speak at 3:00 p.m. ET.
Randal Quarles, Vice Chairman for Supervision, is set to speak at 5:30 p.m. ET.
Dallas Fed President Robert Kaplan will speak at 8:00 p.m. ET.
Federal Reserve Bank of Atlanta President Raphael Bostic is set to speak at 8:00 p.m. ET.
Kansas City Fed President Esther George will speak at 8:00 p.m. ET.
RBC upgraded Benefitfocus (NASDAQ: BNFT) from Sector Perform to Outperform
Stephens upgraded FMC (NYSE: FMC) from Equal-Weight to Overweight
RBC downgraded Colfax (NYSE: CFX) from Outperform to Sector Perform
Deutsche Bank downgraded Smith & Nephew (NYSE: SNN) from Hold to Sell
This is a tool used by the Benzinga News Desk each trading day — it's a look at everything happening in the market, in five minutes. To get the full version of this note every morning, click here.